Cardiovascular Device Market
The future of the global cardiovascular device market looks promising with opportunities in the pacemaker, defibrillator, stent, cardiac catheter, guidewire, heart valve, electrocardiogram, and event monitor markets. The global cardiovascular device market is expected to reach an estimated $117.6 million by 2035 from $88.1 million in 2027 with a CAGR of 3.7% from 2027 to 2035. The major drivers for this market are the rising demand for minimally invasive procedures, the growing adoption of advanced medical technology, and the increasing demand for wearable & remote monitoring devices.
- Lucintel forecasts that, within the type category, interventional cardiac devices is expected to witness the highest growth over the forecast period due to increasing minimally invasive cardiac treatment adoption.
- Within the device category, stent is expected to witness the highest growth over the forecast period due to rising coronary artery disease and stent procedures.
- In terms of regions, North America is expected to witness the highest growth over the forecast period due to growing advanced healthcare infrastructure and treatment demand.
Emerging Trends in Cardiovascular Device Market
From 2025-2027, the cardiovascular device market will shift toward earlier diagnosis, more minimally invasive treatment, and connected follow-up. Capacity constraints and evidence requirements in the hospital environment will affect how purchases are made. Lucintel's expects the market to grow, and changes in reimbursement will vary across different geographic areas.
- Earlier Diagnosis: Artificial intelligence (AI) will play an increasing role in diagnosing cardiovascular disease. The continued development of wearable devices to help detect cardiovascular disease will enable diagnosis to occur outside of the hospital. According to the World Health Organization, Cardiovascular disease is the leading cause of death worldwide, representing approximately 17.9 million deaths in 2019. Faster detection of cardiovascular disease will expand the market for prevention and treatment of cardiovascular disease.
- Minimally Invasive Therapy: In 2025 and beyond, higher volumes of transcatheter aortic valve replacements (TAVRs) will be performed on lower risk patients. Similar to TAVR, catheter based closure of the left atrial appendage and catheter based ablation will become more common. Shorter lengths of stay and improved patient outcomes will drive the changes for a more minimally invasive approach to the treatment of valve disease and atrial fibrillation.
- Connected Care: Implantable devices will be coupled with continuous monitoring to provide real time data. Changes to U.S. reimbursement will drive remote monitoring toward documented outcome and affect the economic decision around follow-up care.
- Outpatient Migration: Ambulatory surgery centers are capturing more cardiovascular surgeries. Hospitals are facing staffing and bed shortages. Procedures that need less anesthesia and less recovery time will gain more of the cardiovascular device spend in 2025-2027.
- Value-Based Procurement: Hospitals will evaluate devices based on total episode cost and clinical outcomes instead of just purchase price; Medtronic expects recurring technology and procedures to grow. Suppliers who have evidence-based products will defend their margins.
Cardiovascular device demand will continue; however, the growth won't be even. Winners will invest in simple, integrated systems. Designing for outpatient care will expand the market and protect margins. Dependence on premium hardware will provide outpatient procurement pressure. Hospitals will evaluate total cost and long-term outcomes.
Recent Developments in the Cardiovascular Device Market
Through 2027, Lucintel's forecasts a fast-growing cardiovascular device market as further advancements in electrophysiology and structural heart, remote monitoring, and minimally invasive vascular care attract greater levels of capital. Lucintel's anticipates a movement by manufacturers to use scale and economic factors to improve clinical evidence.
- Electrophysiology Technology Approvals: In January 2025, Boston Scientific announced U.S. Food and Drug Administration (FDA) approval to expand the indications for their FARAPULSE ablation system to include the treatment of persistent atrial fibrillation. This news creates further competition in the space against thermal ablation and is expected to encourage more research in this area to develop an even faster, more selective ablation technology in the next three to five years.
- Robotic Intervention Partnerships: In March 2025, Medtronic and Siemens Healthiness announced an expanded collaboration to include image-guided and robotic-assisted procedures. The partnership is expected to encourage further research in the integration of navigation, imaging, and interventional device closure to create robot-assisted procedures to help hospitals simplify and standardize various, complex cardiovascular interventions.
- Structural Heart Expansion: Edwards Lifesciences reported 2025 fourth-quarter transcatheter aortic valve replacement (TAVR) sales of approximately $1.1 billion. The trend towards TAVR is expected to encourage other cardiovascular device manufacturers to develop smaller devices and broaden the pool of patients eligible for transcatheter procedures.
- Remote Monitoring: Abbott announced a $200 million expansion of its U.S. manufacturing capacity for connected cardiac devices in June 2025. Greater manufacturing capacity supports its implantable monitors and other devices for the management of cardiac rhythm. Given the increasing importance of the data services, Abbott expects recurring data services to become more material to its revenue.
- Next Generation of Drug-coated Balloons: Terumo launched a next generation drug-coated balloon (DCB) platform in September 2025, expanding competition for the treatment of femoropopliteal intervention. Suppliers of DCBs will need to compete based on the outcomes of vessel patency over the longer term, versus the competing DCBs.
From 2025 through 2027, the cardiovascular device competition will focus on speed and efficiency, with greater use of software, integrated sensors, and remote diagnostics to streamline and improve care capacity of healthcare facilities.
Strategic Growth Opportunities in the Cardiovascular Device Market
Situated between 2024 and 2026, various emerging global trends, including aging and growing populations, increasing levels of obesity, earlier diagnosis of disease, and the physical limitations of healthcare facility capacity, are propelling the cardiovascular device market to undergo significant growth and expansion. Lucintel links these emerging trends to higher volumes of procedures, changes in reimbursement, and a focus on reducing the length of time patients spend in healthcare facilities.
- Remote Cardiac Monitoring: As of January 2025, the FDA cleared software to facilitate ambulatory ECG monitoring to assist in the diagnosis of multiple rhythm conditions. Providers are expected to accelerate the move of the location of follow-up visits from the hospital to the home. With this shift in focus, there will be an increased need to monitor, and intervene upon, patients at an earlier stage.
- Structural Heart Expansion: According to estimates, as of March 2025, the total number of TAVR procedures performed in the U.S. exceeded 500,000. The adoption of TAVR technology, and other structural heart devices, by a wider range of healthcare facilities will continue to increase over the next 3 to 5 years, driven by the expansion of less-invasive procedures performed by interventional cardiologists.
- Peripheral Vascular Devices: In June 2025, the FDA reported that over 8 million Americans are living with peripheral artery disease. There will be growing demand for clinical interventions that facilitate the preservation of lower limbs. This demand will particularly increase due to the more widespread prevalence of diabetes.
- Emerging Market Access: As of February 2025, India's Ayushman Bharat program is estimated to cover more than 500 million beneficiaries. Lower cost designs and local manufacturing can facilitate the growth of cardiovascular device sales within emerging markets.
- Sustainable Device Systems: As of April 2025, the European Union's health care sector was required to expand their compliance to certain elements of sustainability reporting. Cardiovascular devices focused on more sustainable systems of care will gain a greater market presence.
In the next five years, to be successful, companies will have to demonstrate their products in the outpatient setting and adhere to the principles of value based purchasing, including connected health monitoring. Effective integration of Internet of Things technologies will be critical. Sustainable design and manufacturing will become standard. Companies that create a sticky relationship after the sale will gain competitive advantage.
Cardiovascular Device Market Drivers and Challenges
The cardiovascular device market is driven by several factors including more technology, an increase in cardiovascular disease, a growing aging population, investment in healthcare and changing reimbursement policies. Adoption of cardiovascular devices is also impacted by regulatory requirements, supply chain challenges, and cost. Increasingly, competition is based on manufacturing efficiency and the ability to incorporate innovations in digital, wireless and other connectivity in products in a way that positively impacts clinical outcomes, particularly in the cardiovascular space. Competition is also based on how well a company incorporates sustainability into products.
The factors responsible for driving this market include:
- Increasing Cardiovascular Disease Burden: More hypertension, diabetes, obesity and coronary artery disease are increasing demand for diagnostic, interventional and surgical devices. The World Health Organization (WHO) reports cardiovascular diseases as the leading cause of death globally with 17.9 million deaths annually. In the next 3 to 5 years, the aging population and more prevalent lifestyle related risk factors are expected to increase demand for interventional cardiovascular procedures, stents and cardiac monitoring devices, ablation and structural heart devices. To address the growing burden of cardiovascular diseases, healthcare systems are expected to prioritize early detection and prevention and use of home and other types of monitoring and more minimally invasive treatment.
- Minimally Invasive Technology Adoption: Hospitals are increasingly adopting catheter-based and robot-assisted procedures for a variety of reasons including reduction in blood loss, length of stay, and overall treatment burden. The development of TAVR, EP ablation, and other vascular and percutaneous interventions has disrupted the cardiovascular care pathway. The U.S. Food and Drug Administration (FDA) continued reviewing and approving breakthrough cardiovascular devices, thus, reinforcing confidence in less invasive approaches. In the next 3 to 5 years, the enhancement of navigation and imaging systems will extend the eligibility of high-risk patients and motivate the shift of interventional procedures from traditional open surgery.
- Digital Monitoring and Artificial Intelligence: The detection and management of arrhythmias, as well as identification and management of complications from cardiac procedures, have been significantly improved with the integration of advanced sensors, AI and predictive analytics. Wearable ECG monitors with atrial fibrillation and other irregular rhythm notifications facilitated earlier clinical assessment and care outside the hospital in 2025. In the next 3 to 5 years, continued integration and collaboration of telehealth, electronic health records and other electronic systems will establish a 24/7 continuous digital care model and decrease avoidable care management admissions. The cardiovascular care system will only be digitally transformed to the same extent as other care disciplines if clinicians feel assured by clinically validated algorithms, improve data and financial reimbursement pathways for digitally-enabled services.
- Regulatory and Reimbursement Support: Positive regulatory and reimbursement pathways are improving the financial case for developing breakthrough cardiovascular technologies. The 2025 Medicare policies for remote physiological monitoring continued reimbursing eligible connected-care services for meeting documentation and clinical management requirements. The next three to five years are expected to favor devices that yield improved outcomes and cost savings and demonstrate lower readmissions, especially with the increased adoption of value-based payment models. As such, manufacturers will focus on clinical and health economic data and evidence to bolster their approval and reimbursement cases as well as secure procurement contracts with hospitals.
- Manufacturing and Product Innovation: Continued advancements in materials science, microelectronics, automation, sensors and manufacturing are facilitating more innovative and better performing medical devices. These same advancements also make it easier and faster to manufacture medical devices. In 2025, the focus was on delivering medical devices that were thinner, with drug-coated and bioresorbable materials, as well as patient-specific components. The next three to five years are expected to result in innovations that aid in safer and more precise implantation as well as advanced product differentiation. Manufacturing automation and regionalization may improve supply chain reliability, but companies must strike a balance with the other obligations.
The challenges facing this market include:
- High Device Costs and Unequal Access: The high cost of sophisticated cardiovascular devices is due to the high cost of the materials, the need for specialized facilities, trained personnel and long-term follow up. As a result, their use is limited to high income countries. 2025 healthcare systems continue to experience inflation, constraint hospital budgets, and more rigorous evaluation of device purchases. In the next 3 to 5 years, affordability will be a key issue and to address this, companies will need to demonstrate measurable clinical and economic impacts. Local partnerships and a profitable bottom line will be a challenge.
- Complex Regulation and Clinical Evidence: Cardiovascular devices must meet varying regulatory and clinical performance standards in different countries. In 2025 regulators continued to focus on cybersecurity of medical devices and real world data. In the next 3 to 5 years, the use of real world evidence, changes to regulatory requirements and the growing complexity of devices will increase the time to market and the costs of development. Companies will be faced with the need to use partnerships and acquisitions to remain in business, especially if they are small to medium sized companies.
- Supply-Chain, Cybersecurity and Skilled-Labor Risks: Designs relying on specialty metals and semiconductors may encounter supply chain shortages and disruption. Connected devices have cybersecurity and data privacy risks. Innovation in medical procedures increases demand for specialty clinical personnel. In 2025, organizations continued enhancing their cybersecurity controls due to concerns for ransomware and the security of medical devices. It is predicted that over the next 3-5 years, firms will implement multi-source procurement and production in various regions. They will also use secure design of software, and employee training for continuous monitoring. Failure to address these will negatively impact costs, interrupt operations, and diminish confidence of patients and users.
Various factors including improving disease prevalence, increasing demand for minimally invasive treatments, reimbursement changes, and technological advancement create a favorable environment for the cardiovascular device market. There will also be increasing demand for connected, precise and cost-effective devices. However, several challenges including high costs, uncertain and complex regulations, an unpredictable supply chain, and workforce shortages will constrain and delay market growth. Manufacturers that combine the best clinical evidence with robust and secure digital platforms, integrated with flexible pricing strategies, will gain and sustain leadership in the market. The goals for the next 3-5 years will be to improve the health of the population, and improve value and outcomes by using existing healthcare and economic resources.
List of Cardiovascular Device Market Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies cardiovascular device market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cardiovascular device market companies profiled in this report include-
- Abbott Laboratories
- Boston Scientific Corporation
- Edwards Lifesciences Corporation
- Medtronic Public Limited Company
- C. R. Bard, Inc.
- Johnson & Johnson
- St. Jude Medical Inc.
- Cook Medical Inc.
- Terumo Corporation
- Cardinal Health Inc.
Cardiovascular Device Market by Segment
The study includes a forecast for the global cardiovascular device market by type, device, and region.
Cardiovascular Device Market by Type [Value ($M) from 2019 to 2035]:
- Cardiac Rhythm Management
- Interventional Cardiac Devices
- Peripheral Vascular Devices
- Cardiac Assist Devices
- Structural Heart Devices
- Cardiovascular Surgery
- Electrophysiology
- Diagnostic & Monitoring Devices
Cardiovascular Device Market by Device [Value ($M) from 2019 to 2035]:
- Pacemaker
- Defibrillator
- Stent
- Cardiac Catheter
- Guidewire
- Heart Valve
- Electrocardiogram
- Event Monitor
- Others
Cardiovascular Device Market by Region [Value ($M) from 2019 to 2035]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
Country Wise Outlook for the Cardiovascular Device Market
The cardiovascular device market will be shaped by regulatory approvals, localized manufacturing, and strategic investments from 2025 to 2027. Structural heart and robotic platforms, as well as connected platforms and monitoring, will remain key components of the corporate portfolio. From Lucintel's most recent analysis, local policy and technology will impact market positioning.
- United States: The FDA approved Abbott's TriClip edge-to-edge repair system for the tricuspid valve in April 2025. This will expand the structural heart repair pathway in the U.S. and provide a reimbursable pathway for broader adoption of minimally invasive transcatheter edge-to-edge valve repair over the next several years.
- China: Medtronic's Shanghai facility continued to produce more locally made cardiovascular devices, while China's centralized procurement process covered a range of coronary and interventional devices. These will impact how suppliers operate, price their devices, and determine hospital access through 2030.
- Germany: Siemens Healthineers allocated approximately €1.0 billion for fiscal 2025 for research and development, focusing on imaging, intervention, and digital health. This will foster Germany's base in engineering and hospital technology, especially with image-guided cardiovascular procedures. This will further strengthen its position over the next three to five years.
- India: India's production-linked incentive program continued to support the manufacturing of medical devices. During 2025, Meril Life Sciences expanded its cardiovascular business and international operations. Local manufacturing policies with indigenous valve and stent manufacturing platforms can help reduce imports, and strengthen India's role in the region.
- Japan: Terumo continued its focus on interventional cardiology and hospital solutions, reporting a group revenue of ¥1.0 trillion for fiscal 2025. Terumo, with its domestic clinical relationships, and overseas distribution, has the potential to develop and expand advanced catheter-based cardiovascular products.
Features of the Global Cardiovascular Device Market
- Market Size Estimates: cardiovascular device market size estimation in terms of value ($M).
- Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
- Segmentation Analysis: cardiovascular device market size by type, device, and region in terms of value ($M).
- Regional Analysis: cardiovascular device market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different type, device, and regions for the cardiovascular device market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cardiovascular device market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
This report answers following 11 key questions:
- Q.1. What are some of the most promising, high-growth opportunities for the cardiovascular device market by type (cardiac rhythm management, interventional cardiac devices, peripheral vascular devices, cardiac assist devices, structural heart devices, cardiovascular surgery, electrophysiology, and diagnostic & monitoring devices), device (pacemaker, defibrillator, stent, cardiac catheter, guidewire, heart valve, electrocardiogram, event monitor, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
- Q.2. Which segments will grow at a faster pace and why?
- Q.3. Which region will grow at a faster pace and why?
- Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
- Q.5. What are the business risks and competitive threats in this market?
- Q.6. What are the emerging trends in this market and the reasons behind them?
- Q.7. What are some of the changing demands of customers in the market?
- Q.8. What are the new developments in the market? Which companies are leading these developments?
- Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
- Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
- Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?